Bionomics (BNOX) shares surged over 165% in recent trading on Tuesday after the company said it received a milestone payment of AU$1 million ($660,000) from Carina Biotech for BNC101, one of its partnered legacy oncology programs.
The payment was made on Oct. 30 under the exclusive, worldwide license agreement for cancer treatment candidate BNC101, Bionomics added.
The company said it is eligible to receive up to AU$118 million from Carina Biotech conditional on the achievement of certain development, regulatory and commercial milestones.
Price: 0.51, Change: +0.32, Percent Change: +165.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments